JPMorgan Doesn't See A Competing Bid For St. Jude Medical, Downgrades To Neutral

Loading...
Loading...

On April 28, Abbott Laboratories ABT announced the acquisition of St. Jude Medical, Inc. STJ for $82.50 per share.

J.P. Morgan’s Michael Weinstein downgraded the rating on St. Jude Medical from Overweight to Neutral, while raising the price target from $66.00 to $82.50.

The Deal

St. Jude Medical’s shareholders will receive $46.75 in cash and 0.8708 Abbot Laboratories’ shares for every share held by them, based on the latter company’s current share price and representing a 33 percent premium to the former’s closing price on April 27.

The deal has been approved by the boards of both companies and is expected to close in 4Q16.

Competing Bid Unlikely

“In our view, the only other potential suitor for St. Jude with the strategic and financial capabilities would be Johnson & Johnson JNJ, which we view as highly unlikely,” Weinstein stated.

Weinstein pointed out that Johnson & Johnson would run the risk of facing significant anti-trust issues associated with St. Jude Medical’s EP business, which is the latter company’s most attractive asset.

“Combined the two companies control more than 70 percent of the EP market and without that business, it would be hard for J&J to justify paying a premium to what Abbott has announced today,” the J.P. Morgan report said.

Loading...
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorDowngradesPrice TargetAnalyst RatingsJ.P. MorganMichael Weinstein
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...